Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Caris Life Sciences (CAI) to $22 from $28 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where revnue beat but the volume was light.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $32 from $38 at BTIG
- Caris Life Sciences price target lowered to $30 from $35 at JPMorgan
- Caris Life Sciences price target lowered to $28 from $35 at Citi
- Analyst Reiterates Buy as Strong Revenue, Improving Profitability Offset Near-Term Risks; Price Target Trimmed to $31
- Caris Life Sciences Earnings Call Signals Profitable Surge